Renal Anemia – Access & Reimbursement – Access & Reimbursement – Renal Anemia (US)
This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and medical directors. We explore how payers and physicians interact and how reimbursement decisions affect the prescribing and uptake of specific therapies at the brand level.
QUESTIONS ANSWERED
- How do payers reimburse specific therapies for the treatment of renal anemia, and what restrictions do they impose?
- What factors most influence payers’ reimbursement decisions for specific renal anemia therapies?
- What roles do reimbursement, restrictions, and patient costs play in physicians’ choice of therapy for this indication?
- How do payers anticipate reimbursing emerging therapies at various prices?
- What patient share can emerging therapies garner under various reimbursement scenarios?
- How can pharmaceutical companies enable their products to thrive in this market access environment?
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Key Drugs: Aranesp, Epogen, Procrit, Mircera, Retacrit, Auryxia, Roxadustat, Vadadustat, Daprodustat.
Key Companies: Amgen, Johnson & Johnson, Vifor Pharma, Roche, Pfizer, Akebia Therapeutics, FibroGen, AstraZeneca, GSK.
